A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients.

ABSTRACT:

Background & aims

Immune responses of solid organ transplant recipients to 2 doses of the BNT162b2 mRNA anti-SARS-CoV-2 vaccine are impaired. The immunogenicity and safety of a third dose among liver transplant (LT) recipients are unknown. This work aimed to evaluate the immune response of LT recipients to a third dose of the BNT162b2 mRNA vaccine.

Methods

Consecutive LT recipients (n = 61) in follow-up at Sheba Medical Center were included. Receptor binding domain (RBD) IgG, neutralizing antibody (NA) titers, and T-cell levels before and 21-28 days after a third vaccine dose were determined. Adverse effects after the third dose were monitored.

Results

The median age of LT recipients was 65 years and 57.4% were male. The humoral immune response rate improved significa

SUBMITTER: Davidov Y 

PROVIDER: S-EPMC9015954 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature